The Drug Enforcement Administration has rescheduled Epidiolex, paving the way for GW Pharmaceuticals to start selling the first FDA-approved drug derived from cannabis, but stopped short of reclassifying all cannabidiol products. The rescheduling applies to CBD containing no more than 0.1 percent THC, in FDA-approved drug products.
The Food and Drug Administration in June approved Epidiolex, which is derived from cannabidiol, or CBD, a molecule contained in the cannabis plant. This forced the DEA to consider how it would classify Epidiolex since marijuana is considered a schedule 1 drug, which it defines as having no currently accepted medical use and a high potential for abuse.
Epidiolex will be classified as a schedule 5 controlled substance, the lowest level, defined as those with a proven medical use and low potential for abuse. Other drugs in this category include some cough medicines containing codeine.
The drug is indicated to treat patients two years and older with Dravet Syndrome and Lennox-Gastaut Syndrome, rare forms of epilepsy that emerge during childhood and can be difficult to treat. It does not contain tetrahydrocannabinol, or THC, the psychoactive compound in cannabis that makes people high.
GW Pharma said it would "work hard" to make Epidiolex available within the next six weeks. Shares of GW Pharma rose 8 percent on the news and helped pot stocks soar.
"We see our business distinct from Tilray and other companies that are seeking to be active in the broader cannabis space," GW CEO Justin Gover said in an interview Thursday with CNBC's "Power Lunch." "That's a different business. It's not one that we're involved with, but what I would say is this is yet another validation that if you apply the rigors of science and law to cannabis research, that the regulatory authorities, namely the FDA and DEA, will act and respond to the needs of patients to make these kinds of medications available."
The rescheduling applies to CBD containing no more than 0.1 percent THC, in FDA-approved drug products. Though this allows GW Pharma to sell Epidiolex, it does not broadly apply to CBD.
So while oils and lotions are becoming wildly popular, they're still schedule 1 drugs and therefore illegal under federal law, though the DEA typically does not pursue, or enforce the law against, individual users, a DEA spokeswoman told CNBC. Some states have legalized CBD and other marijuana products.
The DEA classifies cannabis as a schedule 1 drug, which it defines as having no currently accepted medical use and a high potential for abuse. Because CBD is a compound found in the cannabis plant, it is considered a schedule 1 drug and therefore illegal.
Coffee shops and other places selling CBD oil may be in line with state laws, depending on where they're located, but they're still skirting federal laws. And though the DEA may not pursue small-scale sellers, it may enforce those federal laws if consumer product conglomerates decide to enter the space.
Beverage giant Coca-Cola in September said although it has "no interest" in cannabis, it's "closely watching the growth of non-psychoactive CBD as an ingredient in functional wellness beverages around the world."
In announcing its approval of Epidiolex, the FDA was clear to distinguish that the drug contains purified CBD and the agency's decision was not a broad approval of the substance. Commissioner Scott Gottlieb said the FDA remains "concerned about the proliferation and illegal marketing of unapproved CBD-containing products with unproven medical claims."